Product Description
The research-grade biosimilar is an antibody-drug conjugate that targets CD79B. CD79B is a transmembrane protein that plays an essential role in B-cell receptor signaling and is highly expressed on the surface of tumorigenic cells. The conjugate consists of Anti-CD79B humanized monoclonal antibody that is linked to a microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, which causes cell cycle arrest and apoptosis of tumorigenic cells. The original antibody-drug conjugate has been approved by the FDA to treat patients with relapsed or refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab.
Biovision | A2178 | Anti-CD79B (Polatuzumab Vedotin), Humanized Antibody DataSheet
Antibody Target: CD79B
Target Alternative Name: B29, IGB, AGM6, fcu 2711, Ro 5541077-000, DCDS4501A, RG7596
Tag Line: The biosimilar is an antibody-drug conjugate that targets CD79B. Upon detachment from the antibody inside the cell, the drug disrupts microtubule network, which leads to cell cycle arrest, and apoptosis of malignant cells
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human CD79B
Accession #: DB12240
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE